Biliary tract cancer outcomes not improved by addition of nab-paclitaxel to standard care.
Annual scientific meetings are off to a big start in 2023 with the 20 year celebratory ASCO GI Symposium held in San Francisco in January.
In the field of rare gastrointestinal cancers, biliary tract cancer updates included a report from the late phase SWOG-1815 clinical trial designed to inform management of advanced disease.
SWOG-1815 overall survival results were presented, with this Phase III study conducted through the National Clinical Trials Network completing recruitment in a rare cancer population (cholangiocarcinoma and gallbladder carcinoma). Overall survival and progression-free survival results were not statistically significant for the addition of nab-paclitaxel to cisplatin gemcitabine in the overall population, with subgroup exploratory analysis identifying trend towards longer survival in the gallbladder cancer (underpowered).
A previous single arm Phase II study found a median overall survival of 19.2 months for this triplet regimen in advance biliary tract cancer, and the successful completion of a subsequent Phase III study is an important undertaking in these rare cancers to optimally inform routine clinical practice.
You can read the whole abstract and others via the ASCO website: